High Prevalence of Hypothyroidism and Approval and Launch of New Products to Augment Growth of Liothyronine Market
Liothyronine is used to treat an underactive thyroid (hypothyroidism) and myxedema coma. It is a manufactured form of the thyroid hormone triiodothyronine.
Market Dynamics
High
prevalence of hypothyroidism is expected to propel growth of the global
liothyronine market. For instance, the study ‘Prevalence of hypothyroidism in
patients with type 2 diabetes mellitus and hypertension in India: a
cross-sectional observational study’, reported that the prevalence of hypothyroidism in patients with
type 2 diabetes mellitus, hypertension, and type 2 diabetes mellitus +
hypertension was 24.8%, 33.5%, and 28.9%, respectively.
High
prevalence of diabetes is also expected to aid in growth of the global
liothyronine market. For instance, according
to the study, “Global and regional diabetes prevalence estimates for 2019 and
projections for 2030 and 2045: Results from the International Diabetes
Federation Diabetes Atlas, 9th edition”, published in the journal Diabetes
Research and Clinical Practice, in September 2019, 463 million people are
expected to suffer from diabetes in 2019 worldwide and the number is expected
to reach 578 million by 2030 and 700 million by 2045.
Side effects of liothyronine
are expected to hinder growth of the global liothyronine market. Excessive
doses of liothyronine may lead to side effects such as weight loss, fever,
headache, anxiety, trouble sleeping, arrhythmias, and heart failure. Moreover,
recall of products is also expected to limit the market growth. For instance, in
January 2020, Wockhardt UK Ltd recalled specific batches of levothyroxine
100micrograms/5ml oral solution due to notification of the impurity
liothyronine exceeding the specification limit. Similarly, in August 2018,
Westminster Pharmaceuticals, LLC recalled Levothyroxine and Liothyronine
tablets in 15 mcg, 30 mcg, 60 mcg, 90 mcg and 120 mcg doses over ingredient
concerns.
Competitive Analysis
Major players operating
in global liothyronine market include, LGM Pharma, LLC, HBCChem, Inc., EMMX
Biotechnology LLC, Zydus Cadila, Wockhardt UK Ltd. Toronto Research Chemicals,
3B Scientific, Apollo Scientific Ltd, American Biochemicals Inc., Acros
Organics B.V.B.A, Suzhou Ryan Pharmaceutical Technology Co, ITL Pharma, Inc,
Bioiberica S.A.U, and Titan Pharmaceuticals, Inc.
Major players operating
in global liothyronine market are focused on approval and launch of new
products to expand their product portfolio. For instance, in January 2021,
Zydus Cadila received the U.S. Food and Drug Administration approval for
marketing Liothyronine Sodium Tablets USP, 5 mcg, 25 mcg, and 50 mcg for the
treatment of hypothyroidism.
Comments
Post a Comment